Почетна › Рак на бели дробови со не-мали клетки › Индијана › Indianapolis
Клинички испитувања за Рак на бели дробови со не-мали клетки во Indianapolis, IN
32 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Indianapolis (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Се регрутираФаза 3
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Се регрутираФаза 3
- Saint Catherine Hospital, Indianapolis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Се регрутираФаза 1
- IU Simon Cancer Center, Indianapolis
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Се регрутираФаза 3
- Franciscan Health ( Site 0219), Indianapolis
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #4, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Се регрутираФаза 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · на 13 милји
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Се регрутираФаза 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Се регрутираФаза 3
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Се регрутираФаза 3
- Franciscan Health, Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Се регрутираФаза 2/3
- Indiana University Health University Hospital, Indianapolis
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Се регрутираФаза 1/2
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Се регрутираФаза 1/2
- Community Health Network, Indianapolis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Се регрутираФаза 3
- Clinical Study Site, Indianapolis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Се регрутираФаза 1
- Community Health Network, Indianapolis
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- Community Health Network, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Се регрутираФаза 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- и уште 1
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Се регрутираФаза 3
- Franciscan Health Indianapolis, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
Се регрутираФаза 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Се регрутираФаза 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Се регрутираФаза 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
A Study of VET3-TGI in Patients With Solid Tumors
Се регрутираФаза 1
- Community Health Network, Indianapolis
Repositioning Immunotherapy in VetArans With Lung Cancer
Се регрутираФаза 2
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Се регрутираФаза 1/2
- Research Site, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Се регрутира
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
Се регрутираНабљудувачка студија
- Community Health Network, Indianapolis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Се регрутира
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Се регрутираФаза 1/2
- Community Health Network, Inc., Indianapolis
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во Indianapolis
- Рак (сите типови)24 студии
- Срцева слабост23 студии
- Дебелина20 студии
- Рак на дојка20 студии
- Метастатски карцином19 студии
- Колоректален карцином18 студии
- Карцином на јајниците17 студии
- Кардиоваскуларни болести17 студии
- Рак на бели дробови16 студии
- Дијабетес тип 114 студии
- Рак на ендометриумот14 студии
- Алцхајмерова болест14 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.